Are we overestimating the loss of beta cells in type 2 diabetes?
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis Previous work has demonstrated that beta cell amount (whether measured as beta cell mass, beta cell volume or insulin-positive area) is decreased in type 2 diabetes; however, recent findings suggest that mechanisms other than death may contribute to beta cell failure in this disease. To better characterise beta cell mass and function in type 2 diabetes, we performed morphological, ultra-structural and functional studies using histological samples and isolated islets.Methods Pancreases from ten non-diabetic (ND) and ten matched type 2 diabetic organ donors were studied by insulin, glucagon and chromogranin A immunocytochemistry and electron microscopy (EM). Glucose-stimulated insulin secretion was assessed using isolated islets and studies were performed using independent ND islet preparations after 24 h exposure to 22.2 mmol/l glucose.Results Immunocytochemistry showed that the fractional islet insulin-positive area was lower in type 2 diabetic islets (54.9 ± 6.3% vs 72.1 ± 8.7%, p < 0.01), whereas glucagon (23.3 ± 5.4% vs 20.2 ± 5.3%) and chromogranin A (86.4 ± 6.1% vs 89.0 ± 5.5%) staining was similar between the two groups. EM showed that the proportion of beta cells in type 2 diabetic islets was only marginally decreased; marked beta cell degranulation was found in diabetic beta cells; these findings were all reproduced after exposing isolated ND islets to high glucose. Glucose-stimulated insulin secretion was 40–50% lower from type 2 diabetic islets (p < 0.01), which again was mimicked by culturing non-diabetic islets in high glucose.Conclusions/interpretation These results suggest that, at least in subgroups of type 2 diabetic patients, the loss of beta cells as assessed so far might be overestimated, possibly due to changes in beta cell phenotype other than death, also contributing to beta cell failure in type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in the late stages of the disease, residual β-cells remain, and their number is possibly underestimated due to absence of markers of β-cell identity in dedifferentiated cells ( 86 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [86]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, there is evidence that β-cell mass in T2DM may have been underestimated due to equating a reduction in insulin staining/content with a reduction in β-cell number (97, 429, 667).”
From Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men (2018) · cites this paper as [429]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011 · cited 3×
“Studies with pancreatic samples obtained at autopsy, from organ donors or after pancreatectomy have shown that beta cell mass is significantly reduced in type 2 diabetic individuals [2–6].”
BackgroundResultInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 1×
“Decreased beta cell functional mass is a hallmark of type 2 diabetes [1, 2].”
BackgroundPancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756 · cited 1×
“Previous work has unequivocably revealed that the beta cell amount in human type 2 diabetes is reduced, mainly due to increased apoptosis, and the implications of this have been widely discussed [2–6, 15, 16].”
Background[Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
Scheen, A. J., & Mathieu, C. (2012) · PubMed · Cited by 581
Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications
Donath, M. Y., & Halban, P. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1336-4 · Cited by 430 · cited 3×
“Studies with pancreatic samples obtained at autopsy, from organ donors or after pancreatectomy have shown that beta cell mass is significantly reduced in type 2 diabetic individuals [2–6].”
BackgroundResultThe endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients
Marchetti, P., Bugliani, M., Lupi, R., Marselli, L., Masini, M., Boggi, U., Filipponi, F., Weir, G. C., Eizirik, D. L., & Cnop, M. (2007) · Diabetologia · doi:10.1007/s00125-007-0816-8 · Cited by 413 · cited 3×
“Islet isolation and functional studies Isolated islets were prepared as described previously [12, 13], and insulin secretion determined by batch incubation (45 min) in response to 3.”
MethodSelf-citationStructural and Functional Abnormalities in the Islets Isolated From Type 2 Diabetic Subjects
Deng, S., Vatamaniuk, M., Huang, X., Doliba, N., Lian, M.-M., Frank, A., Velidedeoglu, E., Desai, N. M., Koeberlein, B., Wolf, B., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.3.624 · Cited by 349
Marselli, L., Thorne, J., Dahiya, S., Sgroi, D. C., Sharma, A., Bonner-Weir, S., Marchetti, P., & Weir, G. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011499 · Cited by 313 · cited 3×
“Islet isolation and functional studies Isolated islets were prepared as described previously [12, 13], and insulin secretion determined by batch incubation (45 min) in response to 3.”
BackgroundMethodResultSelf-citationPancreatic diabetes manifests when beta cell area declines by approximately 65% in humans
Meier, J. J., Breuer, T. G. K., Bonadonna, R. C., Tannapfel, A., Uhl, W. H., Schmidt, W. E., Schrader, H., & Menge, B. (2012) · Diabetologia · doi:10.1007/s00125-012-2466-8 · Cited by 160 · cited 3×
“Since the weight of pancreas specimens was not known, mass values (pancreatic weight × fractional area positive for a given hormone) could not be determined and, in line with previous studies in humans [10, 11], the measurement of area was used as surrogate marker for cell mass.”
MethodResultβ-Cell Mass Dynamics and Islet Cell Plasticity in Human Type 2 Diabetes
Hanley, S. C., Austin, E., Assouline-Thomas, B., Kapeluto, J., Blaichman, J., Moosavi, M., Petropavlovskaia, M., & Rosenberg, L. (2010) · Endocrinology · doi:10.1210/en.2009-1277 · Cited by 156
Beta cell mass in diabetes: a realistic therapeutic target?
Meier, J. J. (2008) · Diabetologia · doi:10.1007/s00125-008-0936-9 · Cited by 155 · cited 1×
“Decreased beta cell functional mass is a hallmark of type 2 diabetes [1, 2].”
BackgroundEffects of Bariatric Surgery on Glucose Homeostasis and Type 2 Diabetes
Bradley, D., Magkos, F., & Klein, S. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.114 · Cited by 152 · cited 1×
“However, beta cell functional defects also play a major role in the pathophysiology of the disease [7], and improvements at this level may better explain, for instance, why 30–100% of patients who have undergone bariatric surgery may show diabetes remission within a few days after surgery and only a 1–2%weight loss [8…”
BackgroundType 2 Diabetes, Insulin Secretion and β-Cell Mass
Ahren, B. (2005) · Current Molecular Medicine · doi:10.2174/1566524053766004 · Cited by 143 · cited 3×
“Studies with pancreatic samples obtained at autopsy, from organ donors or after pancreatectomy have shown that beta cell mass is significantly reduced in type 2 diabetic individuals [2–6].”
BackgroundResultAltered Islet Composition and Disproportionate Loss of Large Islets in Patients with Type 2 Diabetes
Kilimnik, G., Zhao, B., Jo, J., Periwal, V., Witkowski, P., Misawa, R., & Hara, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027445 · Cited by 132 · cited 2×
“In accordance with previous studies [13, 14], light microscopy revealed that the islets varied in terms of size, insulin- and glucagon-positive areas, and they either retained a normal architecture or instead displayed sparse architecture (ESM Fig.”
BackgroundResultGoals of Treatment for Type 2 Diabetes
Marchetti, P., Lupi, R., Guerra, S. D., Bugliani, M., D’Aleo, V., Occhipinti, M., Boggi, U., Marselli, L., & Masini, M. (2009) · Diabetes Care · doi:10.2337/dc09-s306 · Cited by 70 · cited 2×
“However, beta cell functional defects also play a major role in the pathophysiology of the disease [7], and improvements at this level may better explain, for instance, why 30–100% of patients who have undergone bariatric surgery may show diabetes remission within a few days after surgery and only a 1–2%weight loss [8…”
BackgroundSelf-citationWeighing up β-cell mass in mice and humans: Self-renewal, progenitors or stem cells?
Hanley, N. A., Hanley, K. P., Miettinen, P. J., & Otonkoski, T. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.03.001 · Cited by 40
Tancredi, M., Marselli, L., Lencioni, C., Masini, M., Bugliani, M., Suleiman, M., Masiello, P., Boggi, U., Filipponi, F., Dotta, F., et al. (2011) · Islets · doi:10.4161/isl.3.5.15940 · Cited by 11 · cited 2×
“Since the weight of pancreas specimens was not known, mass values (pancreatic weight × fractional area positive for a given hormone) could not be determined and, in line with previous studies in humans [10, 11], the measurement of area was used as surrogate marker for cell mass.”
MethodResultSelf-citation
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men
Rorsman, P., & Ashcroft, F. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00008.2017 · Cited by 793
The Role of Oxidative Stress and Hypoxia in Pancreatic Beta-Cell Dysfunction in Diabetes Mellitus
Gerber, P. A., & Rutter, G. A. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6755 · Cited by 654
“…to which decreased beta-cell mass (24) and dysfunction (35) contribute to the impairments in insulin production in T2D is contested (168), although recent estimates of relatively minor changes ( * 24% at diagnosis) in the former (112) have placed the onus on dysfunction as the important driver.”
Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes
Cinti, F., Bouchi, R., Kim-Muller, J. Y., Ohmura, Y., Sandoval, P. R., Masini, M., Marselli, L., Suleiman, M., Ratner, L. E., Marchetti, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2860 · Cited by 550
Self-citationChen, C., Cohrs, C. M., Stertmann, J., Bozsak, R., & Speier, S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.019 · Cited by 489
Metadata
- Authors
- Marselli, L., Suleiman, M., Masini, M., Campani, D., Bugliani, M., Syed, F., Martino, L., Focosi, D., Scatena, F., Olimpico, F., Filipponi, F., Masiello, P., Boggi, U., & Marchetti, P.
- Affiliations
- University of Pisa (IT)
- Ospedale Cisanello (IT)
- Corresponding author
- Marchetti, Piero
- ORCID
- Venue
- Diabetologia
- Published
- 2013-11-15
- Volume
- 57
- Issue
- 2
- Pages
- 362-365
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2052524549
- Cited by
- 136
- References
- 18
- Citations by year
- 2025: 7 · 2024: 10 · 2023: 12 · 2022: 14 · 2021: 17 · 2020: 12 · 2019: 12 · 2018: 15 · 2017: 11 · 2016: 9 · 2015: 8 · 2014: 9
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- European Federation of Pharmaceutical Industries and Associations (FP7/20072013)
- European Commission (2007–2013, FP7 2007-2013, FP7/2007)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 2 diabetes, beta cell destruction, beta-cell mass, beta-cell failure, beta cell degranulation, glucose-stimulated insulin secretion, islet ultrastructure, glucagon, chromogranin A, high glucose
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Female, Glucagon, Humans, Immunohistochemistry, Insulin, Male, Microscopy, Electron, Pancreas, Insulin-Secreting Cells, Chromogranin A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.